Key Takeaways Shares of Krystal Biotech (KRYS) gained 4.2% on Tuesday after the company announced that it has dosed the first patient in the late-stage study evaluating its investigational candidate, KB803, for the treatment and prevention of corneal abrasions in dystrophic epidermolysis bullosa (DEB). KB803 is administered as an eye drop. Krystal Biotech's only marketed product, Vyjuvek, is currently FDA-approved for treating patients aged six months or older with DEB. The drug is referred to as B-VEC outs ...